JPM23

Biotech Jonathan Wosen

STAT Plus: FDA’s Califf says congressional report on Aduhelm controversy contained ‘no surprises’

Biotech Adam Feuerstein

STAT Plus: New Biogen CEO: New drug launches, more cost cuts, but no ‘radical left turns’ needed

Biotech Matthew Herper

STAT Plus: BioMarin executives express confidence around hemophilia gene therapy

Business Bob Herman and Tara Bannow

STAT Plus: The health care providers and insurers we’re watching at JPM23 — and why

Biotech Adam Feuerstein and Allison DeAngelis

STAT Plus: Money troubles and M&A: What’s on biotech insiders’ minds ahead of a not-so-celebratory JPM week

Biotech Jonathan Wosen

STAT Plus: Invitae’s new CEO on why the genetic testing firm stopped chasing ‘volume at all costs’

Biotech Matthew Herper

Virtual Event: “JPM Recap, Live!” 2023

Biotech Allison DeAngelis

STAT Plus: Biotech startups are hungry for dollars. Here’s what one pharma executive was looking for at JPM